In cooperation with


Diagnostics of human papillomavirus virus infection

Cervical cancer is one of the best preventable malignancies with regard to primary and secondary prevention. This tumor essentially depends on a persistent infection of the uterine cervix with high risk human papillomavirus (HR-HPV). Currently HR-HPV diagnostics are mainly integrated as triage test in the German screening program which is based on annual pap smears. To further lower the incidence of the invasive cervical cancer (which has been steady for decades) HR-HPV based screening in women of 30 years and older might be more effective. Consequently, more and more countries are currently introducing a HRHPV test-based strategy. This article discusses the role of HPV testing in both screening settings and tries to give an insight into the current discussion.

CME Prakt Fortbild Gynakol Geburtsmed Gynakol Endokrinol 2016; 12(2): 158–171

Cervical cancer, human papillomavirus (HPV), HPV screening, cervical intraepithelial neoplasia (CIN), vaccination

Inga Bohlmann, Linn Wölber
Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-
Eppendorf, Hamburg
Reviewer: Andreas M. Kaufmann, Berlin,
und Alexander Luyten, Wolfsburg

Bohlmann I. HPV-Diagnostik Gynakol Geburtsmed Gynakol Endokrinol 2016; 12(2): 158–171 publiziert 31.7.2016 ©akademos Wissenschaftsverlag 2016 ISSN 1614-8533